Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Cytotekk who wrote (121)	4/11/1998 1:41:00 AM
From: fut_trade	Read Replies (1) \| Respond to of 178

Colleen, thanks for your input. I recently took a position in NPTH after I learned the Soros owns more than 5% of the company. Peter

To: Cytotekk who wrote (121)	4/11/1998 12:56:00 PM
From: Sigmund	Read Replies (1) \| Respond to of 178

<<<Papnet is a system that is too costly<<< True but the same can be said for AutoPap too although obviously not to the same extent. I don't see how primary screening contributes much to improved diagnosis. It eliminates those slides which have nothing on them so that doesn't identify any cancers or precancers. Do you disagree with this? How does it improve diagnosis? And it certainly doesn't save the labs any money. So that is why I conclude that it is noneconomic at this point in time. Others will develop economic approaches for sure.